

Notice from annual general meeting in Xintela AB (publ)

Today, Friday 6 May 2022, the annual general meeting in Xintela AB (publ) was held. The following main resolutions were passed.

Allocation of results and discharge from liability

The meeting resolved, in accordance with the board's proposal, that no dividend shall be paid for the financial year 2021 and that the company's result shall be carried forward.

Furthermore, the meeting resolved on discharge of the members of the board of directors and the managing director from liability for the financial year 2021.

Appointment of and fees payable to members of the board of directors and auditor

The meeting resolved that the board of directors shall be composed of four ordinary members with no deputies. Gregory Batcheller, Lars Hedbys and Maarten de Chateau were re-elected as members of the board of directors, and Hans-Joachim Simons was appointed new member of the board of directors. Gregory Batcheller was re-elected chairman of the board.

Moreover, the meeting resolved on remuneration to the board of directors amounting to SEK 750,000 in total, whereby SEK 300,000 shall be distributed to the chairman of the board and SEK 150,000 to each of the other board members.

The meeting also resolved to re-elect Öhrlings PricewaterhouseCoopers AB as auditor and that remuneration to the auditor shall be paid in accordance with approved invoices.

New articles of association

The meeting resolved, in accordance with the board's proposal, to adopt new articles of association whereby the limits for the number of shares and share capital are amended.

Issue authorizations

The meeting resolved, in accordance with the board's proposal, to authorize the board, within the limits stipulated in the articles of association and with pre-emptive rights for the company's shareholders, to resolve to issue new shares or to issue convertibles or warrants.

Further, the meeting resolved, in accordance with the board's proposal, to authorize the board to, with deviation from the shareholders' pre-emptive rights, resolve to issue new shares or to issue convertibles or warrants. Issue resolutions based on the authorization may not entail that the total number of shares increases with more than 20 percent of the total number of shares outstanding in the company on the day of the meeting. The

purpose of the authorization, and the reason for the deviation from the shareholders' pre-emptive rights, is to enable the company to broaden the shareholder base, raise or enable raising of working capital, increase the liquidity in the share, pursue acquisitions or raise or enable capital raising to make acquisitions.

Distribution of shares in the company's subsidiary

The meeting finally resolved, in accordance with the board's proposal, that all shares in the wholly-owned subsidiary Targinta AB (publ) shall be distributed to Xintela's shareholders, whereby one share in Xintela entitles to one share in Targinta AB (publ).

The meeting further resolved, in accordance with the board's proposal, to authorise the board of directors to determine the record date for the right to receive shares in Targinta AB (publ), however not later than on the day before the annual general meeting 2023. The dividend resolution as well of the board's resolution on record date shall be conditional upon that the shares in Targinta are admitted for trading on a multilateral trading platform.

Contacts

Xintela AB (publ)

Evj Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evj@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Press Release
06 May 2022 10:45:00 CEST



Attachments

[Notice from annual general meeting in Xintela AB \(publ\)](#)